The primary goal of this R21 is to generate data on the behavior of a new type of PET scan, tau-PET, in subjects diagnosed with primary progressive aphasia (PPA) and the three well recognized variants of PPA: agrammatic, semantic and logopenic PPA. Pathological studies have identified an abnormal protein, tau, as being an important player in the neurodegenerative process. Tau is thought to be one of the leading causes of neurodegenerative diseases. It was not possible however, until recently, to determine whether tau deposition was present in the brain during life. An imaging ligand AV-1451 (formerly 18F-T807) was recently developed, which specifically binds to tau in human brains. No studies have investigated tau binding in PPA using neuroimaging. Over the 2 years of the R21 we will recruit subjects with all three PPA variants and compare AV-1451 binding in PPA and PPA variants, to AV-1451 binding in normal control subjects to get an estimate of what proportion of PPA subjects and PPA variants do test positive for tau with AV-1451. We will also assess whether there is any evidence that binding patterns for tau differs across the three PPA variants. In our final aim we will use the unbiased technique of cluster analysis to determine whether there is any support for clinico-anatomically defined PPA variants based on binding patterns of tau with AV-1451, independent of the clinically defined PPA variants. These are important steps that are necessary to move the field forward given that tau-PET is a new technique with little existing data to draw upon for hypothesis testing. Therefore, this R21 will b important to generate hypotheses for a future R01.The proposal is novel and feasible. To accomplish our aims, we will perform detailed neurological, speech and language, and neuropsychological testing, as well as the new AV-1451 PET scan and volumetric head MRI scanning. The Principal Investigator of this grant, Dr. Keith Josephs is a world renowned neurodegenerative specialist who has assembled a team of world renowned experts in speech and language (Dr. Joseph Duffy), neuroimaging (Drs. Clifford Jack, Val Lowe, Jennifer Whitwell) and neuropsychology (Dr. Mary Machulda) to collectively work to address the aims. The team will have state of the art facilities and equipment in order to do so.

Public Health Relevance

This study will perform detailed clinical evaluations, head MRI scan, and a new type of brain scan, to better understand how an abnormal protein known as tau is associated with primary progressive aphasia. This is an important study because there are ongoing tau drug treatment trials that could benefit people with this devastating disorder and lead to future improvements in treatment. We estimate that tens of thousands of Americans suffer from primary progressive aphasia so this study could have a major public health impact.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Exploratory/Developmental Grants (R21)
Project #
1R21NS094684-01
Application #
9014263
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Babcock, Debra J
Project Start
2016-05-15
Project End
2018-04-30
Budget Start
2016-05-15
Budget End
2017-04-30
Support Year
1
Fiscal Year
2016
Total Cost
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Utianski, Rene L; Duffy, Joseph R; Savica, Rodolfo et al. (2018) Molecular neuroimaging in primary progressive aphasia with predominant agraphia. Neurocase 24:121-123
Josephs, Keith A; Martin, Peter R; Botha, Hugo et al. (2018) [18 F]AV-1451 tau-PET and primary progressive aphasia. Ann Neurol 83:599-611
Tetzloff, Katerina A; Graff-Radford, Jonathan; Martin, Peter R et al. (2018) Regional Distribution, Asymmetry, and Clinical Correlates of Tau Uptake on [18F]AV-1451 PET in Atypical Alzheimer's Disease. J Alzheimers Dis 62:1713-1724
Utianski, Rene L; Whitwell, Jennifer L; Schwarz, Christopher G et al. (2018) Tau-PET imaging with [18F]AV-1451 in primary progressive apraxia of speech. Cortex 99:358-374
Tetzloff, Katerina A; Whitwell, Jennifer L; Utianski, Rene L et al. (2018) Quantitative assessment of grammar in amyloid-negative logopenic aphasia. Brain Lang 186:26-31
Whitwell, Jennifer L; Graff-Radford, Jonathan; Tosakulwong, Nirubol et al. (2018) [18 F]AV-1451 clustering of entorhinal and cortical uptake in Alzheimer's disease. Ann Neurol 83:248-257
Botha, Hugo; Duffy, Joseph R; Whitwell, Jennifer L et al. (2018) Non-right handed primary progressive apraxia of speech. J Neurol Sci 390:246-254
Tetzloff, Katerina A; Duffy, Joseph R; Strand, Edythe A et al. (2018) Clinical and imaging progression over 10 years in a patient with primary progressive apraxia of speech and autopsy-confirmed corticobasal degeneration. Neurocase 24:111-120
Utianski, Rene L; Botha, Hugo; Duffy, Joseph R et al. (2018) Rapid rate on quasi-speech tasks in the semantic variant of primary progressive aphasia: A non-motor phenomenon? J Acoust Soc Am 144:3364
Whitwell, Jennifer L (2018) Tau Imaging in Parkinsonism: What Have We Learned So Far? Mov Disord Clin Pract 5:118-130

Showing the most recent 10 out of 16 publications